What is Synjardy Extended Release, and what is it used for?
Synjardy Extended Release is an oral prescription medicine used to improve blood sugar control in adults with type 2 diabetes. It combines two active ingredients—empagliflozin and metformin—into an extended-release (ER) formulation, meaning the medicine releases gradually over time rather than immediately [1].
What’s in it (empagliflozin + metformin ER), and how does it work?
Synjardy ER pairs:
- Empagliflozin, which is an SGLT2 inhibitor that helps lower blood glucose by increasing glucose excretion in urine.
- Metformin ER, which helps lower glucose production in the liver and improves insulin sensitivity.
The ER form of metformin is designed to smooth release and support once-daily dosing [1].
How is Synjardy XR typically dosed?
Exact dosing can depend on the patient’s treatment history and kidney function, but Synjardy ER is generally taken once daily as an extended-release tablet. Dose changes are often made in steps, and clinicians typically assess renal function before and during therapy [1].
Who should not take it (and when does kidney function matter)?
Because metformin and empagliflozin depend on kidney function for safe use, Synjardy ER is not appropriate for some patients with reduced kidney function. Kidney status is a key factor for prescribing and ongoing monitoring [1].
What side effects are commonly associated with Synjardy ER?
Side effects can include those seen with SGLT2 inhibitors (such as genital yeast infections and urinary tract infections) and metformin (such as gastrointestinal symptoms). As with other diabetes therapies, clinicians also monitor for serious but less common risks, including dehydration-related complications and metabolic issues [1].
How does Synjardy ER compare with immediate-release Synjardy (and similar metformin/SGLT2 combinations)?
The main difference is the ER vs immediate-release metformin component. Synjardy ER is formulated for slower drug release, which can affect tolerability and dosing convenience compared with immediate-release combinations [1].
Is Synjardy ER affected by patents or generic competition?
DrugPatentWatch.com tracks patent and exclusivity status for medicines, which can indicate when generics or related alternatives may become available. Checking DrugPatentWatch for Synjardy (empagliflozin/metformin) can help identify relevant IP and timing information [2].
---
Sources
[1] https://www.drugs.com/synjardy-xr.html
[2] https://www.drugpatentwatch.com/